Rhenman & Partners Asset Management’s Janux Therapeutics JANX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-225,377	Closed	-$3.11M	–	96
2025 Q4	$3.11M	Buy	225,377 +125,250	+125%	+$2.95M	0.29%	78
2025 Q3	$2.45M	Buy	100,127 +45,000	+82%	+$1.1M	0.27%	79
2025 Q2	$1.27M	Sell	55,127 -86,500	-61%	-$2.28M	0.16%	83
2025 Q1	$3.82M	Sell	141,627 -28,373	-17%	-$1.07M	0.44%	52
2024 Q4	$9.1M	Buy	170,000 +63,153	+59%	+$3.34M	0.94%	41
2024 Q3	$4.85M	Hold	106,847	–	–	0.39%	66
2024 Q2	$4.48M	Buy	106,847 +2,347	+2%	+$110K	0.43%	58
2024 Q1	$3.93M	Buy	+104,500	New	+$2.28M	0.37%	58

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Rhenman & Partners Asset Management's JANX Position: Q1 2026 in Review

Rhenman & Partners Asset Management sold out of Janux Therapeutics (JANX) in Q1 2026, closing a stake of 225,377 shares — an estimated $3.11M sold.

Rhenman & Partners Asset Management first reported a position in JANX in Q1 2024 and held it in 8 quarters. The position peaked at $9.1M in Q4 2024. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

Rhenman & Partners Asset Management reported no remaining Janux Therapeutics position as of Q1 2026 after selling out during the quarter.
Rhenman & Partners Asset Management sold 225,377 Janux Therapeutics shares in Q1 2026, an estimated $3.11M.
Rhenman & Partners Asset Management first reported a position in Janux Therapeutics in Q1 2024 and held it in 8 quarters.
Rhenman & Partners Asset Management's Janux Therapeutics position peaked at $9.1M in Q4 2024.
190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.